Estrella Immunopharma (ESLA) vs Pluri (PLUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Estrella Immunopharma (ESLA) has outperformed Pluri (PLUR) over the past year, losing 67.9% versus a loss of 75.5%. Over five years, PLUR leads with a -95.2% price change compared with -95.8% for ESLA. Estrella Immunopharma is the larger company by market cap ($17.2 million vs $12.6 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ESLA | PLUR |
|---|---|---|
| Share price | $0.3949 | $1.00 |
| Market cap | $17.18M | $12.61M |
| 1-day change | -5.48% | 0.00% |
| YTD return | -73.24% | -66.56% |
| 1-year return | -67.88% | -75.49% |
| 5-year return | -95.77% | -95.23% |
| EPS (TTM) | $-0.25 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.15 | $4.87 |
| 52-week low | $0.3083 | $0.85 |
| Distance from 52-week high | -87.46% | -79.47% |
| Analyst consensus | none | — |
| Avg. price target upside | +2938.74% | — |
| Average volume | 38.61K | 24.97K |
| Shares outstanding | 43.50M | 12.61M |
| Employees | — | 92 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Estrella Immunopharma
ESLA stock →Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees
ESLA vs PLUR FAQ
Which is bigger, Estrella Immunopharma or Pluri?
Estrella Immunopharma (ESLA) is larger, with a market capitalization of $17.18M compared with $12.61M for Pluri (PLUR).
Which stock has performed better over the past year, ESLA or PLUR?
ESLA returned -67.88% over the past 12 months, compared with -75.49% for PLUR (price return, excluding dividends). Past performance does not predict future results.
Are Estrella Immunopharma and Pluri in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.